180TiP Palbociclib, trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype (SOLTI-1303 PATRICIA II): A randomized phase II trial

Autor:	E. Martínez, Mafalda Oliveira, Andreu Prat, X. González-Farré, T. Pascual, Antonia Perelló, B. Bermejo De Las Heras, S. Pernas Simon, M. Mele Olive, J. Cortés, Maria Jose Echarri, Patricia Villagrasa, I. Garau Llinas, Blanca Cantos, E.M. Ciruelos, Nerea Martinez, Alvaro Montaño, S. Vázquez, Pamela Céliz, Estela Vega
Rok vydání:	2020
Předmět:	Oncology medicine.medical_specialty business.industry Endocrine therapy Hematology Palbociclib medicine.disease Breast cancer Trastuzumab Hormone receptor Internal medicine medicine business medicine.drug
Zdroj:	Annals of Oncology. 31:S80-S81
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2020.03.280
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::db88a283b1ca84c9028b26cf0223af48 https://doi.org/10.1016/j.annonc.2020.03.280 Zobrazit plný text záznamu